Trial Profile
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail to Achieve a Complete Response to Initial Gleevec Treatment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Arsenic trioxide (Primary) ; Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 04 Jun 2009 New trial record.